Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
CNS & Neurological Disorders Drug Targets
|
May 22, 2007
The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders
John H Kehne
CNS & Neurological Disorders Drug Targets
|
April 14, 2007
Depression
Ronald S Duman, John H Kehne
CNS & Neurological Disorders Drug Targets
|
May 22, 2007
Depression
Ronald S Duman, John H Kehne
Pharmacology & Therapeutics
|
September 10, 2010
Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models
John H Kehne, Christopher K Cain
Current Topics in Medicinal Chemistry
|
August 12, 2008
D2 receptor partial agonists: treatment of CNS disorders of dopamine function
John H Kehne, Terrance H Andree, Julia N Heinrich
Expert Opinion on Investigational Drugs
|
July 28, 2012
Targeting memory processes with drugs to prevent or cure PTSD
Christopher K Cain, George D Maynard, John H Kehne
Neurochemical Research
|
May 3, 2017
The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)
John H Kehne, Brian D Klein, Shamsi Raeissi, et al.
Psychopharmacology
|
November 25, 2010
Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals
James K Rowlett, John H Kehne, Ken J Sprenger, et al.
Journal of Sleep Research
|
August 18, 2009
Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans
Peter T Morgan, John H Kehne, Ken J Sprenger, et al.
Journal of Clinical Pharmacology
|
February 26, 2013
The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers
Michael J Avram, Daniel A Spyker, John H Kehne, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
CNS & Neurological Disorders Drug Targets
|
May 22, 2007
The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders
John H Kehne
CNS & Neurological Disorders Drug Targets
|
April 14, 2007
Depression
Ronald S Duman, John H Kehne
CNS & Neurological Disorders Drug Targets
|
May 22, 2007
Depression
Ronald S Duman, John H Kehne
Pharmacology & Therapeutics
|
September 10, 2010
Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models
John H Kehne, Christopher K Cain
Current Topics in Medicinal Chemistry
|
August 12, 2008
D2 receptor partial agonists: treatment of CNS disorders of dopamine function
John H Kehne, Terrance H Andree, Julia N Heinrich
Expert Opinion on Investigational Drugs
|
July 28, 2012
Targeting memory processes with drugs to prevent or cure PTSD
Christopher K Cain, George D Maynard, John H Kehne
Neurochemical Research
|
May 3, 2017
The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)
John H Kehne, Brian D Klein, Shamsi Raeissi, et al.
Psychopharmacology
|
November 25, 2010
Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals
James K Rowlett, John H Kehne, Ken J Sprenger, et al.
Journal of Sleep Research
|
August 18, 2009
Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans
Peter T Morgan, John H Kehne, Ken J Sprenger, et al.
Journal of Clinical Pharmacology
|
February 26, 2013
The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers
Michael J Avram, Daniel A Spyker, John H Kehne, et al.
Page
of 2